Chronic Kidney Disease Overview
Chronic Kidney Disease Overview
Chronic kidney disease is the long-term loss of kidney function, and its defining feature is that it is quiet: most people have no symptom at all until the disease is well advanced. That is why it is defined by measurement rather than by complaint — two numbers, one from the blood and one from the urine, taken three months apart. This guide follows the path patients actually take: what those two numbers mean, what is causing the damage, what genuinely slows it, and how dialysis and transplantation are planned rather than arrived at by surprise.
-
2 numbers
define the disease — filtration rate and albumin in the urine
-
2004
the year our nephrology department was established
-
30+
haemodialysis machines, with 20 specialised beds and 2 CRRT machines
-
20,000
kidney outpatient visits a year, and close to 1,000 inpatient admissions
What chronic kidney disease is — and why it is defined by numbers, not symptoms
The kidneys filter the blood, and everything else they do follows from that: they balance water and salt, they hold the blood's chemistry within the narrow range cells can tolerate, they make the hormones that keep bones strong and blood circulating, and they clear the medicines the body has finished with. Chronic kidney disease is the long-term, usually progressive loss of that work.
It is defined by measurement rather than by how a person feels, because for most of its course it produces nothing to feel. A person can lose a substantial share of their filtering capacity and notice no change at all; by the time tiredness, swelling or nausea appear, the disease has usually been running for years. This is the single most important thing to understand about it, because it explains everything else: the diagnosis is made by a blood test and a urine test, the severity is expressed in categories rather than in adjectives, and progress is tracked as a slope on a chart rather than as a change in wellbeing.
The definition has two parts, and either one is enough. The first is a filtration rate — eGFR — that has been below 60 ml/min/1.73 m² for at least three months. The second is a marker of damage, most importantly albumin in the urine, even when the filtration rate is still normal. Both must be present on at least two occasions months apart, because a single abnormal reading can be a passing state rather than a chronic one.
One further distinction shapes every conversation that follows. Acute kidney injury happens over hours or days, often has a visible cause — an infection, a medicine, a blocked catheter, a bout of severe dehydration — and frequently recovers. Chronic kidney disease is measured over months and years. The two overlap: an acute injury laid on top of chronic disease is the commonest reason a stable patient suddenly deteriorates, and protecting against those episodes is part of managing the chronic one.
The causes behind the label, and why the cause decides the treatment
"Chronic kidney disease" is a description of function, not of cause — like "anaemia" or "heart failure". Six broad mechanisms produce it, and the label alone does not say which one is at work. Establishing the cause is not an academic exercise: immune diseases are treated with immune suppression, obstruction is treated by relieving it, diabetic kidney disease is treated with the medicines that also protect the heart, and a medicine that is quietly injuring the kidneys is stopped. Treating the number without treating the cause is how years pass with a stable chart and a progressive disease.
| Cause | What is happening | How it usually presents | What it means for treatment |
|---|---|---|---|
| Diabetes | Years of high glucose damage the filtering units' small vessels and the membrane that holds protein back | Albumin appearing in the urine, then a slow fall in filtration rate; often no symptom at all | Glucose control plus the medicines that protect the kidney independently of glucose — blood pressure agents and SGLT2 inhibitors |
| High blood pressure | Sustained pressure damages the same small vessels the kidney depends on, and the kidney's own pressure regulation is lost in a loop | Long-standing hypertension, often with modest protein leak; the two conditions worsen each other | Pressure treated to target, usually with agents that also lower pressure inside the filtering unit |
| Glomerular and immune disease | The immune system attacks the filtering units themselves — IgA nephropathy, lupus nephritis and their relatives | Blood and protein in the urine, sometimes after an infection; can fall quickly and can present younger | Immune suppression where the pattern and the risk justify it; this is where biopsy most often changes the plan |
| Cystic and inherited disease | Cysts replace working tissue over decades — polycystic kidney disease being the commonest | A strong family history, enlarged kidneys on imaging, hypertension appearing early | No disease-modifying treatment for the cysts themselves; the work is blood pressure, complications and planning |
| Obstruction and reflux | Urine cannot drain freely — stones, an enlarged prostate, a narrowed junction — and pressure backs up into the kidney | Flank pain or recurrent infection; often silent until function has already fallen | Relieve the obstruction; this is one of the few causes where function can improve after treatment |
| Unknown or multiple | No single cause found, or several acting together — commoner than most patients expect, particularly when the disease is already advanced | Late presentation with small, scarred kidneys, where the original cause has left no fingerprint | Treatment aimed at what is measurable: pressure, albuminuria, complications, and protection from further injury |
Notice the pattern in the last column. The cause decides the treatment, and in one row above the treatment is a procedure rather than a medicine. That is why finding the cause is written into the assessment rather than treated as an optional extra.
The two numbers that stage it: filtration rate and albumin
Staging is not one scale but two read together, because they carry partly independent information. The first, G, is how much filtering capacity remains. The second, A, is how much protein is leaking — which predicts both how fast function will fall and how much cardiovascular risk is attached. A person with a normal filtration rate and heavy protein leak is not in the same position as a person with the same filtration rate and none, and the staging says so.
| Category | What the test shows | What it means in practice |
|---|---|---|
| G1–G2 | Filtration rate 60 or above — normal or near-normal | Not chronic kidney disease on this number alone; it becomes CKD when a marker of damage such as albuminuria is present |
| G3a | Filtration rate 45–59 | Mild-to-moderate reduction. Complications begin to appear here — blood pressure, bone chemistry, anaemia — and monitoring becomes structured |
| G3b | Filtration rate 30–44 | Moderate-to-severe reduction. Referral to a kidney specialist is expected, and planning for the future starts while the person feels well |
| G4 | Filtration rate 15–29 | Severe reduction. Preparation for kidney replacement — education, access planning, transplant assessment — is the work of this stage, undertaken early rather than late |
| G5 | Filtration rate below 15, or on dialysis | Kidney failure. Dialysis or transplantation is needed; the question is which, and on whose timetable |
The albumin axis runs from A1, where the urine is normal or near-normal, through A2 — a moderate increase that already signals higher risk — to A3, a heavy leak that accelerates loss of function and carries the greatest cardiovascular risk. The two axes are written together: G3b A3 and G3b A1 are the same filtration rate and different diseases.
Two consequences follow from reading staging this way. First, the number that most repays attention is the trend rather than the value: a filtration rate of 52 that has been 88, 70 and 52 over three years is a more urgent finding than a stable 52 of a decade's standing. Second, staging is what makes a written plan transferable — a team in another country can read "G3b A3, falling by about 5 a year" and know exactly where a patient stands.
What a full kidney assessment actually contains
The assessment is mostly blood and urine, and it is arranged so that each test answers one question. Very little of it is exotic. The failure mode is not that the tests are unavailable; it is that only some of them were done, and a conclusion was drawn from half a picture.
| Test | What it measures | What it answers |
|---|---|---|
| eGFR from creatinine | Filtering capacity, estimated from a blood measurement that is cheap, standardised and widely available | How much function remains — the G of the staging. Read as a trend, never as an isolated value |
| Urine albumin-to-creatinine ratio | The leak of protein into urine, corrected for how concentrated the sample is | The A of the staging, and the strongest single predictor of how fast function will be lost |
| Blood pressure, including home readings | The pressure the kidney's vessels are being asked to withstand, outside the consulting room | Both a cause and an accelerator; the number that most treatments are aimed at |
| Kidney ultrasound | Size, shape, scarring, and whether urine is draining freely | Whether the disease looks chronic — small, scarred kidneys — and whether obstruction is present, which is one of the reversible causes |
| Blood chemistry panel | Haemoglobin, calcium, phosphate, parathyroid hormone, bicarbonate, potassium and the rest | Which complications have already begun, so they can be treated rather than waited for |
| Kidney biopsy | A small sample of kidney tissue read under several kinds of microscope | What the disease actually is, where the answer would change the treatment. Not needed for every patient; decisive for some |
Immune and metabolic blood tests — antibodies, complement, protein electrophoresis, HbA1c — are drawn in the same pass, because they are the difference between a label and a mechanism. The diagnosis page sets out what each is for and where a biopsy genuinely changes the plan.
Why patients travel to China for chronic kidney disease
Our nephrology department was established in 2004 and is the leading unit of the Fosun Health Nephrology Specialty Alliance, led by Associate Professor Liu Xiaogang. It runs an outpatient clinic, inpatient wards and a haemodialysis unit with 20 specialised beds, more than 30 haemodialysis machines and 2 CRRT machines, and handles nearly 20,000 kidney outpatient visits and close to 1,000 inpatient admissions a year.
The equipment matters to a specific group of patients: Fresenius haemodialysis machines, haemodiafiltration machines and CRRT, a secondary reverse osmosis water treatment system, a haemodialysis information management system and a centralised fluid supply system. So does the range of work the department does under one roof — primary and secondary kidney disease including IgA nephropathy, diabetic kidney disease and lupus nephritis; hyperuricaemia, gout and urate nephropathy; comprehensive chronic kidney disease management; peritoneal dialysis catheter placement; vascular access establishment and maintenance; and double plasma exchange and hybrid blood purification.
What patients mostly travel for, though, is not a machine but an answer. A large share of the international enquiries we receive come from people whose condition has been monitored but never explained: a filtration rate that has been falling for years with no cause ever established, proteinuria that nobody has investigated, or a biopsy that was never offered. The assessment described on the diagnosis page is built around closing that gap, and it is performed from records before any travel is discussed.
For patients who are already on dialysis, travel is a different and more practical question, and it is answered on the practical questions page: whether a dialysis schedule can be arranged here, what records are needed, and how treatment continues after the patient goes home.